Core Scientific Inc. has been the subject of a proposed merger with CoreWeave. The transaction, involving an announced exchange ratio, has drawn scrutiny following its announcement, with market reactions indicating that Core Scientific shareholders viewed the terms as less favorable than expected. Subsequent trading dynamics, including early volatility in CoreWeave shares and opposition from some Core Scientific shareholders, have contributed to ongoing skepticism about the deal's perceived fairness and likelihood of closing. Advisory firms Glass Lewis and ISS have highlighted concerns about the valuation and the lack of mechanisms to protect Core Scientific shareholders from downside risk, such as a collar or partial cash component, noting that recent market activity and the company's standalone prospects suggest potential for greater shareholder value outside of the transaction.